Roth MKM Reiterates Buy on Immix Biopharma, Maintains $14 Price Target
BenzingaAug 14, 2023 10:11 ET
Immix Biopharma Analyst Ratings
BenzingaAug 14, 2023 10:10 ET
Roth MKM Keeps Their Buy Rating on Immix Biopharma, Inc. (IMMX)
TipRanksFeb 28, 2023 08:41 ET
Immix Biopharma Analyst Ratings
Benzinga Analyst RatingsFeb 22, 2023 08:28 ET
Roth MKM Initiates Coverage On Immix Biopharma With Buy Rating, Announces Price Target of $14
Benzinga Real-time NewsFeb 22, 2023 08:21 ET
No Data
No Data